The Journal of Experimental Medicine
Aegean Conferences: 2009 Conferences
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published 7 January 2002. doi:10.1084/jem.20011578
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 134K)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marculescu, R.
Right arrow Articles by Nadel, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marculescu, R.
Right arrow Articles by Nadel, B.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Lymphoma
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© Rockefeller University Press, 0022-1007/2002/1/85/ $5.00
The Journal of Experimental Medicine, Volume 195, Number 1, January 7, 2002 85-98


Original Article

V(D)J-mediated Translocations in Lymphoid Neoplasms : A Functional Assessment of Genomic Instability by Cryptic Sites



Rodrig Marculescu1, Trang Le1, Paul Simon2, Ulrich Jaeger1 and Bertrand Nadel1

1 Department of Internal Medicine I, Division of Hematology
2 Department of Surgery, University of Vienna, A-1090 Vienna, Austria

Address correspondence to Bertrand Nadel, Department of Internal Medicine I, Division of Hematology, University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. Phone: 43-1-40400-4999; Fax: 43-1-40400-7842; E-mail: Bertrand.Nadel{at}akh-wien.ac.at

Most lymphoid malignancies are initiated by specific chromosomal translocations between immunoglobulin (Ig)/T cell receptor (TCR) gene segments and cellular proto-oncogenes. In many cases, illegitimate V(D)J recombination has been proposed to be involved in the translocation process, but this has never been functionally established. Using extra-chromosomal recombination assays, we determined the ability of several proto-oncogenes to target V(D)J recombination, and assessed the impact of their recombinogenic potential on translocation rates in vivo. Our data support the involvement of 2 distinct mechanisms: translocations involving LMO2, TAL2, and TAL1 in T cell acute lymphoblastic leukemia (T-ALL), are compatible with illegitimate V(D)J recombination between a TCR locus and a proto-oncogene locus bearing a fortuitous but functional recombination site (type 1); in contrast, translocations involving BCL1 and BCL2 in B cell non-Hodgkin's lymphomas (B-NHL), are compatible with a process in which only the IgH locus breaks are mediated by V(D)J recombination (type 2). Most importantly, we show that the t(11;14)(p13;q32) translocation involving LMO2 is present at strikingly high frequency in normal human thymus, and that the recombinogenic potential conferred by the LMO2 cryptic site is directly predictive of the in vivo level of translocation at that locus. These findings provide new insights into the regulation forces acting upon genomic instability in B and T cell tumorigenesis.

Key Words: LMO2 • TAL2 • TAL1 • BCL2 mbr • BCL1 mtc


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS